OTLK Latest Press Releases

-- October 9, 2026 --

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer Globe Newswire 8:30 AM

-- October 6, 2026 --

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion Globe Newswire 9:20 AM

-- October 1, 2026 --

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA (bevacizumab-vikg) Globe Newswire 9:01 AM

-- September 11, 2026 --

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand Globe Newswire 7:00 AM

-- September 10, 2026 --

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA in Virtual Investor CEO Connect Segment Globe Newswire 9:10 AM

-- August 27, 2026 --

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA Globe Newswire 4:05 PM

JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs ACCESS Newswire 9:01 AM

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor 'Why Now' On-Demand Conference Globe Newswire 9:01 AM

-- August 14, 2026 --

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA Globe Newswire 7:15 AM

-- August 12, 2026 --

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants Globe Newswire 9:45 PM

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants Globe Newswire 4:01 PM

-- August 6, 2026 --

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026 Globe Newswire 8:45 AM

-- July 24, 2026 --

Outlook Therapeutics Announces LYTENAVA FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD Globe Newswire 2:40 PM

-- June 16, 2026 --

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA (bevacizumab-vikg) as a Treatment for Wet AMD Globe Newswire 8:02 AM

Market Data Delayed 15 Minutes